Serplulimab for locally advanced cervical cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a new immunotherapy drug, serplulimab, for people with locally advanced cervical cancer. The goal is to see if it can help shrink or control the cancer before standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with a type of cervical cancer called squamous cell, adenocarcinoma, or adenosquamous carcinoma.
- Your cancer is locally advanced (stage IB2-IIB with positive lymph nodes, or stage III-IVA) and has not spread to distant parts of your body.
- You are between 18 and 75 years old.
- You have not had any prior anti-tumor treatment for this cancer.
- Your overall health is good enough to perform daily activities (ECOG score 0 or 1).
- You are willing to use effective contraception during the study and for 6 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests combining two drugs (nituzumab and serplulimab) with focused radiation to treat cervical cancer that has not responded to other therapies. The goal is to see if this combination can shrink tumors and improve outcomes.
This trial tests a new drug called Rulonilimab combined with chemotherapy, with or without bevacizumab, as the first treatment for cervical cancer that has spread or come back. It’s for people whose tumors have a specific marker (PD-L1) and who haven’t had other treatments for advanced disease.
This trial tests a combination of cadonilimab (an immune-boosting drug) plus chemotherapy for locally advanced cervical cancer that hasn't been treated before. The goal is to see if this combination helps shrink tumors and improve outcomes before surgery.
This trial tests a combination of three types of cancer-fighting drugs—an immunotherapy (camrelizumab), a targeted therapy (famitinib), and chemotherapy—to treat cervical cancer that has returned or spread. The goal is to see if this combination works better than standard treatment.
This trial tests if giving chemotherapy plus an immunotherapy drug before surgery can help shrink tumors and improve outcomes for patients with stage IB2 cervical cancer that has not been treated yet. It might be an option if you have a specific type of cervical cancer that shows a certain protein (PD-L1) on your tumor cells.
This trial tests adding an immunotherapy drug (serplulimab) to standard chemoradiation after cervical cancer surgery. It is for patients with at least two high-risk features, like lymph node spread or deep invasion, to see if it helps prevent the cancer from coming back.
Hear when a new Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.